Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2018-06-30
2022-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective of this study is to evaluate the ovarian reserve before and after the implementation of antiretroviral treatment in PLWH for whom the diagnosis of HIV has just been made.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AMH and Pregnancy Rate by Age During Stimulate In-Vitro Fertilization Protocol
NCT01762111
Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
NCT05969574
What is the Best Moment for Performing an HSG in Women With a Unfulfilled Childwish
NCT05608590
Evaluation of Child Desire in Young Women With Premature Ovarian Failure
NCT04881695
Long-term Ovarian Fertility in Patients Treated for Lymphoma.
NCT05616325
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
case
PLWH
AMH test
Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
pelvic ultrasound
Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
control
HIV negative women, going to medically assisted procreation consultation for male infertility
AMH test
Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
pelvic ultrasound
Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AMH test
Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
pelvic ultrasound
Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* woman aged 18 to 37
* covered by social security
* able to give an informed consent
Case group only :
* diagnosis of HIV infection during the 3 months before inclusion
* concomitant initiation of an antiretroviral therapy with integrase inhibitors and nucleoside analogues
Control group only :
* assisting medically assisted procreation consultation for male infertility
* matching case subjects with age, BMI and smoking habits
Exclusion Criteria
* current pregnancy
* condition or associated treatment that may have an impact on fertility
* premature ovarian failure
* polycystic ovary syndrome
* endometriosis
Control group only :
\- suspected HIV infection
18 Years
37 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Florence BRUGNON
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Clermont-Ferrand
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A03469-44
Identifier Type: OTHER
Identifier Source: secondary_id
CHU-391
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.